AI-Powered Precision Learning: Optimizing Frontline Treatment Decision-Making in Chronic Lymphocytic Leukemia: Integrating Biomarkers, Clinical Evidence, and Patient-Centered Care

The frontline management of chronic lymphocytic leukemia (CLL) has never offered more promise or demanded greater clinical precision. Biomarker-guided treatment selection and an expanding arsenal of targeted therapies are redefining standards of care. However, clinicians continue to face challenges integrating biomarker data, clinical evidence, and patient-specific factors when selecting frontline therapy, particularly for older adults and medically complex patients. Treatment-related toxicities associated with Bruton tyrosine kinase (BTK) inhibitors and venetoclax-based regimens further require proactive monitoring and multidisciplinary management to preserve treatment continuity. To deliver individualized, evidence-based care with confidence, clinicians need practice grounded in realistic clinical scenarios.

In this AI-powered precision learning activity, learners will work through real-world scenarios that require integration of biomarker testing results, current clinical evidence, and patient-specific characteristics to guide personalized frontline treatment decisions including the choice between fixed-duration and continuous treat-to-progression approaches. Throughout the activity, learners will further be challenged to tailor therapy for older and medically complex patients and apply evidence-based multidisciplinary strategies to monitor and manage treatment-emergent toxicities in support of treatment continuity and optimal patient outcomes.

At the conclusion of this activity, learners will be able to better:

• Integrate biomarker data, clinical trial evidence, and patient-specific factors to individualize frontline treatment selection in CLL
• Individualize frontline treatment selection for older or medically complex patients with CLL
• Apply evidence-based, monitoring and management strategies for treatment-related toxicities associated with BTK inhibitor– and venetoclax-based regimens, leveraging team-based care to optimize treatment continuity and patient outcomes in frontline CLL

Supported through an independent educational grant from AstraZeneca Pharmaceuticals.

General medical oncologists, hematologic oncologists, hematologists, oncology advanced practice providers (APPs), and other health care professionals involved in the management of patients with CLL

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Faculty

Dr. Woyach reports the following financial relationships:

Advisory Board: AbbVie Inc.; AstraZeneca; BeOne Medicines; Genentech, Inc.; Johnson & Johnson; Lilly; Merck & Co., Inc.; and Newave Pharmaceutical Co., Ltd.

Consultant: AbbVie Inc.; AstraZeneca; BeOne Medicines; Genentech, Inc.; Johnson & Johnson; Lilly; Merck & Co., Inc.; and Newave Pharmaceutical Co., Ltd.

Research Support: Merck & Co., Inc.; Newave Pharmaceutical Co., Ltd.; and Schrodinger, Inc.

Patient Planner

Philip L. Witt reports no financial relationships to disclose.

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Susan Perry (Planning Committee)
Taylor Wallace, PhD (Planning Committee)
Leijah Petelka (Planning Committee)
Andrea Perseghin, EdD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.